Babban Sakamako daga Maganin Alamomin Menopause

A KYAUTA Kyauta 4 | eTurboNews | eTN
Avatar na Linda Hohnholz
Written by Linda Hohnholz

Astellas Pharma Inc. a yau ta sanar da sakamako mafi girma daga mataki na 3 SKYLIGHT 4™ gwajin asibiti wanda ke binciken lafiyar dogon lokaci na fezolinetant, wani bincike na baka, wanda ba na hormonal ba wanda ake nazarinsa don maganin matsananciyar cututtuka na vasomotor da ke hade da menopause (VMS) zai goyi bayan ƙaddamar da ƙaddamar da ƙa'idodi na gaba. VMS, wanda ke da walƙiya mai zafi (wanda kuma ake kira zafi mai zafi) da/ko gumi na dare, alamu ne na gama gari na menopause.1,2      

SKYLIGHT 4 bazuwar, mai sarrafa wuribo, gwajin asibiti na mataki biyu na makafi a cikin mata sama da 3 da ke binciken lafiyar dogon lokaci (makonni 1,800) na fezolinetant a cikin matan da ke neman magani don samun sauƙi na VMS mai alaƙa da menopause. Babban makasudin binciken shine kimanta tasirin fezolinetant akan lafiyar endometrial da aminci na dogon lokaci da jurewar fezolinetant. An cimma matakin farko na tantance lafiyar endometrial kuma mafi yawan abubuwan da suka faru na rashin lafiya (TEAE) sune ciwon kai da COVID-52, daidai da placebo. Bayanin saman layi yana ƙara siffanta bayanin martabar aminci na dogon lokaci na fezolinetant kuma za su sanar da takaddun tsari na gaba. Za a ƙaddamar da cikakken sakamako don bugawa kuma don yin la'akari a taron likita masu zuwa.

"Bisa ga kimar mu na farko, mun gamsu da sakamakon binciken SKYLIGHT 4, wanda ya kara nuna lafiyar dogon lokaci na fezolinetant," in ji Nancy Martin, MD, PharmD, Mataimakin Shugaban Kasa, Shugaban Kiwon Lafiya na Duniya, Kwararrun Kiwon Lafiya, Astellas. . "Tare da waɗannan bayanan da ba a iya gani ba, muna fatan za mu sami damar sadar da aji na farko, zaɓin jiyya na marasa hormonal don matsakaici zuwa matsananciyar VMS mai alaƙa da menopause."

"An ba da rahoton bayyanar cututtuka na Vasomotor a matsayin mafi yawan alamun bayyanar cututtuka na menopause, duk da haka an sami ƙananan ƙididdiga a cikin wannan yanki na warkewa," in ji Genevieve Neal-Perry, MD, Ph.D., Shugaban, UNC School of Medicine Department of Obstetrics da kuma Gynecology. "Na yi farin ciki da yuwuwar sabon zaɓin jiyya ba na hormonal ga matan da ke fuskantar matsakaici zuwa matsananciyar VMS mai alaƙa da menopause."

Sakamakon SKYLIGHT 4, tare da sakamako daga manyan gwaje-gwajen asibiti na Phase 3, SKYLIGHT 1™ da SKYLIGHT 2™, za su samar da bayanan tushe don ƙaddamar da tsari a cikin Amurka da Turai.

Fezolinetant ne mai zaɓaɓɓen neurokinin-3 (NK3) antagonist mai karɓa na bincike. Ana binciken aminci da ingancin fezolinetant kuma ba a tabbatar da shi ba. Idan hukumomin da suka tsara sun amince da su, fezolinetant zai zama ajin farko, zaɓin jiyya na marasa hormonal don rage yawan mita da tsananin VMS mai alaƙa da menopause.

Game da marubucin

Avatar na Linda Hohnholz

Linda Hohnholz

Edita a shugaba don eTurboNews bisa ga eTN HQ.

Labarai
Sanarwa na
bako
0 comments
Bayanin Cikin Lissafi
Duba duk maganganu
0
Za a son tunanin ku, don Allah sharhi.x
()
x
Share zuwa...